comprehensive -WSS

comprehensive

author：fashion 2025-09-08 19:11:48 - browse：91

De-Shaine Murray is working at the cutting edge of neurotechnology. As a postdoctoral fellow at Yale, he is developing a device to monitor the brain following traumatic brain injury or stroke.

He is also trying to fight the long legacy of racism in neuroscience. During 2020, when it was difficult to conduct research, he said, “I got the chance and the ability to read more widely and to just look into the legacy of neuroscience.” He found a direct line from racist pseudoscience like phrenology to disparities in neuroscience today, like how the texture of Black people’s hair can sometimes exclude them from clinical trials because electrodes are not designed for them. In 2021, he co-founded Black in Neuro, an organization dedicated to improving Black representation in neuroscience.

On this episode of the “First Opinion Podcast,” I spoke to him about how the past and present racism in neuroscience could be reflected in the future, especially as neurotechnology like brain implants become more common.

“I’m not saying that whatever electrode that you made or created is racist. But when you have someone who … creates a technology but doesn’t think about the wide range of users that are potentially going to use it, then that’s where the problem comes in,” he told me.

We also discussed the way inequities in neuroscience research are visible in stroke wards, how brain implants might jump from helping disabled people to being used for human enhancement, and more.

Our conversation was inspired by his recent First Opinion essay, “Neuroscience has to grapple with a long legacy of racism if it wants to move into the future.” The book I mention at the end is “Lock In” by John Scalzi, a great sci-fi mystery exploring themes of race, socioeconomic status, neurotechnology, and more.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： At least 13 dead in Texas as scorching temps continue

WSS

When women are denied an abortion, their children fare worse than peers

Activists slam private health insurers over coverage restrictions

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

When women are denied an abortion, their children fare worse than peers

New air purifier tech could be key to improving indoor air quality

FDA panel signals lack of confidence in Amgen cancer drug data

knowledge

comprehensive

LETTER TO THE EDITOR

Have an opinion on this essay? Submit a letter to the editor here.

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Analysis of telehealth claims data suggest service duplication

Activists slam private health insurers over coverage restrictions

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Trump demands the U.S. pay no more for drugs than other countries … again

BioMarin wins approval for gene therapy to treat hemophilia A

Tori Bowie and the unacceptable rates of Black maternal death

Chemotherapy drug shortage eases slightly but still widespread

Supreme Court strikes down use of affirmative action

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

focus

3 questions for the future of Biden's cancer moonshot

Colorectal cancer study finds potential in overlooked immune cell

Phenylephrine and the overlooked value of the placebo effect

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Sports medicine is finally prioritizing gender equality

Heart attack and stroke risk calculators need revising

knowledge

Wikipedia

entertainment

focus